Method for integrated treatment of early anal squamous cell carcinoma

FIELD: medicine.

SUBSTANCE: method involves teletherapy combined with a local electromagnetic hyperthermia, chemotherapy with cisplatin and bleomycin, metronidazole as an ingredient of a composite mixture introduced through rectum. Teletherapy is conducted with using a continuous course of 3D and IMRT planning with photons 6-18 MeV covering the tumour and regional metastases in a single basic dose of 1.6 to 1.8 Gy daily 5 times a week, 27-30 fractions, in a total radiation dose of 48.0-48.6 Gy. At the same time, the tumour is exposed to teletherapy with using a simultaneous integrated boost in a single basic dose of 2.0 to 2.2 Gy, 27-30 fractions, in a total radiation dose of 59.4-60.0 Gy.

EFFECT: method enables reducing a radiation exposure, a teletherapeutic dose on the surrounding critical structure, saving the time and conducting a fewer sessions of teletherapy, ensuring lower intensity and the number of toxic reactions, the total length of treatment, eliminating early recurrences.

2 ex

 

The invention relates to medicine, namely to Oncology, to methods of complex treatment of squamous cell cancer of the anal canal in stage T1-2NoMo.

Known methods of complex treatment of squamous cell cancer of the anal canal with the use of conformal radiation therapy in different modes fractionation in combination with chemotherapy. The increase in total focal dose (SOD) radiation therapy with concomitant administration of chemotherapy can increase overall survival up to 89% and relapse-free survival of 75% (R. Glynne-Jones, et. al. /Anal Cancer: an examination of radiotherapy strategies / Int. J. Radiation Oncology Biol. Phys., Vol.79, N 5, pp.1290-1301, 2011).

Closest to the claimed method (prototype) is a method of treating squamous cell cancer of the anal canal with the use of radiation therapy in 2 stages, chemotherapy with cisplatin and bleomycin, the local electromagnetic hyperthermia and metronidazole as part of a composite mixture (Patent RF №2427399).

The disadvantages of the prototype are:

- the development of toxic reactions, which leads to longer intervals up to 3-4 weeks between treatment stages;

early relapses during the year.

The task of the invention is to create a new effective method of complex treatment of early-stage squamous cell cancer of the anal canal.

The technical result

The inventive method the integral treatment of early-stage squamous cell cancer of the anal canal can reduce radiation dose and lower-dose radiation therapy to the surrounding critical structures, to reduce the time and number of sessions of radiation therapy, to reduce the intensity and amount of toxic reactions, the total duration of treatment, to exclude early relapses.

The problem is solved in that a new method of complex treatment of early-stage squamous cell cancer of the anal canal, including a continuous course of radiation and chemotherapy, and radiation therapy is a combination of remote conformal radiation therapy, intensity modulated beam (IMRT - intensity modulated radiation therapy) using simultaneo integrated boost (SIB); local electromagnetic hyperthermia; chemotherapy with cisplatin and bleomycin and metronidazole as part of a composite mixture introduced vnutriuretrale. The composite mixture contains the following ratio of ingredients in the mass. %: metronidazole 12-22, sodium alginate 4-6, dimethylsulfoxide - 2, distilled water to 100 (patent RF №2352359).

The method was carried out as follows.

Radiation therapy was performed by the technology of remote multi-field conformal radiation therapy mode IMRT photons 6-18 MeV. Radiation exposure was subjected to the pelvic area, including inguinal, adrectal, obturatorious, external and internal iliac, the lymph nodes, single focal dose (GENUS) of 1.6-1.8 Gy daily, 5 times a week is Yu from 27 to 30 fractions, SOD from 48.0 to 48.6 per Gr. At the same time on the area of the primary tumor irradiation was performed through the use of SIB daily GENUS of 2.0-2.2 Gy per fraction, 5 days a week from 27 to 30 fractions, SOD from 59,4 to 60.0 Gr.

To reduce the radiation load on the region of the bladder and more accurate marking zone exposure should position the patient on his back with a filled bladder and fixation device under his feet.

Before the 1st, 2nd and 16th sessions of radiation therapy performed control evaluation and correction of patient positioning errors using system portal megavoltage imaging beam of a linear accelerator of electrons OBI - On Board Imaging.

The local electromagnetic hyperthermia started after 8 sessions of radiotherapy in SOD from of 16.0 to 17.6 Grams 2 times a week immediately before the radiation therapy apparatus Yacht-4" in the microwave mode of radio waves with a frequency of electromagnetic oscillations 460 MHz for 60 minutes at a temperature in the tumor 42,5-43,0°C, 4-5 sessions.

Metronidazole in the composition of the composite mixture was introduced vnutriuretrale at a dose of 10 mg/m2for 5 hours to perform local electromagnetic hyperthermia for 5 hours on the background of the water load 2 times for the course. Simultaneously with radiation therapy was chemotherapy with cisplatin intravenously at a dose of 20 mg/m2in the 1st and 3rd days of last week the irradiation, 8 injection; bleomycin intramuscularly at a dose of 15 mg/m2prior radiation therapy and local electromagnetic hyperthermia in the 2nd and 4th days of the week, 8 injection.

The claimed method of treatment received in 11 patients. 9 patients (81.8 percent) treatment performed in full and on schedule. The effect is a complete regression of the tumor after 3 months after treatment. In 2 patients (18.1 percent) in connection with rectitem, cystitis, grade II (RTOG/EORTC) treatment completed on SOD 56,0 G on the area of the primary tumor, regional metastasis sites - SOD 44,8 Gr.

Early complications of radiation and chemotherapy were treated within 1 month of medical treatment on an outpatient basis.

Example 1

Sore Feet

Clinical diagnosis: cancer of the anal canal with the spread on the skin of the perianal region T2NoMo.

Morphological diagnosis: squamous cell carcinoma with a tendency to keratinization.

In magnetic resonance imaging from 28.04.2012, revealed thickening of the walls of the anal canal up to 1.5 cm, the initial infiltration of the distal part of the internal sphincter. Diagnosed with a tumor of the anal canal with the spread on the perianal region.

If rektoromanoskopii from 03.04.2012, the front wall of the anal canal the anal sphincter discovered an ulcer the size of a 2.0-1.0 cm, covering the mucous membrane of the Ana is inogo channel.

With 02.05.2012 on 14.06.2012, were treated by the claimed method.

After treatment, the General condition, slight pain when urinating, moderate hyperemia of the skin in the radiation zone.

At follow-up at 3 months (28.09.2012,) no complaints, reactions cropped.

When the control rektoromanoskopii from 12.10.2012, the tumor is not defined.

According to transrectal ultrasound transrectal us) complete regression of the tumor.

Example 2

Patient O.

Clinical diagnosis: cancer of the anal canal T2NoMo.

Morphological diagnosis: 29.06.2012, - poorly-differentiated squamous cell carcinoma.

If rektoromanoskopii at a height of 4.0 cm from the entrance to the anal canal is determined by education, not stenocereus the lumen of the anal canal, with a rough pitted surface, length 2,0, see

According to the transrectal us in the rectum in front semicircle is defined by the oval hypoechoic education dimensions of 0.8 to 0.6-1.1 cm with irregular indistinct contours, enlarged regional lymph nodes are not defined.

With 03.07.2012 on 10.09.2012, were treated by the claimed method.

When control over in 1.5 months. (23.10.2012,) the tumor was not found.

According to the transrectal us from 07/12/2012 diagnosed with complete regression of the tumor.

The way to the integrated treatment of early-stage squamous cell cancer of the anal canal, includes remote radiation therapy in combination with local electromagnetic hyperthermia, chemotherapy with cisplatin and bleomycin, metronidazole as part of a composite mixture, wherein the radiation therapy is carried out using 3D planning technology IMRT photons 6-18 MeV continuous rate to the region of the tumor and regional metastasis sites ROD from 1.6 to 1.8 Gy daily, 5 times a week, 27-30 fractions, SOD 48,0 is 48.6 Gy, while conducting radiation therapy on the tumor using simultaneo integrated boost GENUS from 2.0 to 2.2 G, 27-30 fractions, SOD to 59.4 60,0 Gr.



 

Same patents:

FIELD: medicine.

SUBSTANCE: blood prostate specific antigen is measured. Radiation therapy is carried out, and Zoladex 3.6 mg is administered every 28 days before, during and after radiation. If the blood PSA is lower than 1 ng/ml three months after the beginning of the Zoladex therapy, administering the preparation is continued for the following 6 months. Radiation therapy involves a split course in the regimen of the common radiation dose fractionation to the total radiation dose 64 Gy. If the blood PSA is found to be below 1 ng/ml only six months after the beginning of the Zoladex therapy, administering the preparation is continued for the following 9 months. Radiation therapy involves the split course in the regimen of the common radiation dose fractionation to the total radiation dose 70 Gy. If the blood PSA is above 1 ng/ml six months later, Zoladex is administered in a combination with Casodex 50 mg administered daily for the following 12 months. Radiation therapy involves the split course in the regimen of the common radiation dose hypofractionation to the total radiation dose 70 Gy.

EFFECT: higher effectiveness and optimisation of treatment, substantial reduction of a number of complications on the part of a wide range of a patient's body systems, and prolonged remission.

3 ex

FIELD: chemistry, pharmaceutics.

SUBSTANCE: invention relates to thieno[3,2-d]pyrimidine derivative of formula (I) or to its pharmaceutically acceptable salt: (I), where Y stands for -CH=CR1-, -C≡C- or -C(=O)NR1-; L stands for -C(=O)NR2-, -NR2C(=O)- or -NR2C(=O)NR2-; R1 and R2, each independently stands for H; R stands for H, a halogen atom, methyl or methoxy; E stands for phenyl or C3-10heteroaryl, which is non-substituted or substituted with 1-2 substituents, consisting of a group, which includes a halogen atom, -CF3, C1-6alkyl, hydroxy-C1-6alkyl, C3-8cycloalkyl, -(CH2)n-C1-6alkylamino, -(CH2)n-diC1-6alkylamino, -(CH2)nC1-6alkoxy, -(CH2)n-OS(=O)2-C1-6-alkyl, -(CH2)n-phenyl, -(CH2)n-C2-5heteroaryl and -(CH2)n-C4-6heterocycloalkyl, where C3-10heteroaryl represents pyridine, isoquinoline, indole or isoxazole, C2-5heteroaryl of radical -(CH2)n-C2-5heteroaryl represents imidazole or pyrrol, C4-6heterocycloalkyl of radical -(CH2)n-C4-6heterocycloalkyl represents piperazine, morpholine, diazepam, pyrrolidine or piperidine, and phenyl, heteroaryl and heterocycloalkyl each independently, is non-substituted or substituted with substituent selected from a group, which consists of C1-6alkyl, hydroxy-C1-6alkyl, a halogen atom and diC1-6alkylamino, n is equal to 0 or 1; and Z stands for H, -C(=O)R3, C1-6alkyl, hydroxyC1-6alkyl, C3-8cycloalkyl, piperidine, phenyl or pyridine, where piperidine, phenyl and pyridine, each independently, is non-substituted or substituted with C1-6alkyl, C1-6alkoxy or R3-piperazinyl and R3 represents C1-6alkyl or phenyl. The invention also relates to an intermediate compound for obtaining the claimed final compound of formula (I).

EFFECT: novel compound, which can be applied in medicine for the prevention or treatment of diseases, characterised by an anomalous growth of cells as a result of an excessive expression of proteinkinase, is obtained.

8 cl, 2 tbl, 128 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: described is a specific list of various novel azaazulene compounds, which contain 6,5-condensed heterocycle of an indole type, benzimidazole type, purine type, 3H-imidaso[4,5-b]pyrene,3H-imidaso[4,5-c] pyridine, etc., which can be described by the general formula , where R1 is =O; R2 is H or diethylaminoalkyl; R3-R7 is H; other variables in the formula (I) are given in the specific structural formulas of the described compounds. A pharmaceutical composition which contains thereof is also described.

EFFECT: compounds possess an anti-tumour activity and can be used for treatment of cancer, such as breast cancer, lung cancer, pancreas cancer, cancer of large intestine, and acute myeloid leukemia.

5 cl, 2 dwg, 6 tbl, 14 ex

FIELD: medicine.

SUBSTANCE: claimed group of inventions relates to medicine, namely to oncology and radiology, and can be applied for treatment of cancer tumours. For this purpose an oil emulsion of a true solution of a radioactive salt of a short-lived isotope is introduced into a tumour in the form of separate portions by a specified programme. Also realised are the following energetic influence and control. For this purpose a coaxial sensor of temperature and/or pH are introduced into the tumour. Sensors are connected to a measuring apparatus and sources of electric impulses. Supply of electric current makes it possible to additionally realise an increase of the damaging action on irradiated cells of the cancer tumour by periodically controlled passing of series of electric impulses through the tumour until a ionisation ablation or a temperature of destruction of protein molecules and DNA of cancer cells. Also is claimed a method, which includes illumination of the tumour by an external source of directly ionising charged particles by the specified program in the form of separate portions. The coaxial sensors of temperature and/or pH, connected to the measuring apparatus and the source of electric impulses, are introduced into the cancer tumour. Supply of electric impulses in the tumour provides a local increase of the damaging action on irradiated cells of the cancer tumour until the ionising ablation or the temperature of protein molecules and DNA cancer cells destruction is provided.

EFFECT: claimed group of inventions ensures reduction of treatment terms and reduction of its trauma with more intensive destruction of cancer cells due to an additional impact of electric current with a small dose of ionising radiation.

9 cl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to conjugates for the delivery of medications, which bind receptors on the cell surface, containing hydrophilic linker spacers.

EFFECT: claimed conjugates are intended for visualisation, diagnostics and treatment of painful conditions, caused by populations of pathogenic cells.

38 cl, 19 dwg, 49 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine and deals with a pharmaceutical composition for enhancing the efficiency of treatment of liver cancer by Sorafenib, with the said composition containing an anti-glypican 3-antibody as an active ingredient.

EFFECT: invention provides an improved anti-cancer effect and reduction of the side effect, in particular loss of the body weight.

14 cl, 9 dwg, 2 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed is a group of inventions, which includes a method of treating a hyperproliferative disorder by introduction to a mammal of a therapeutic combination in the form of a combined composition or by alternation, and the therapeutic combination contains a therapeutically effective quantity of formula compound 4-(2-(1H-indasol-4-yl)-6-((4-(methylsulphonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine, or formula (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one, or their stereoisomers, geometrical isomers, tautomers, or their salts and a therapeutically effective quantity of a chemiotherapeutic agent, selected from erlotinib, docetaxel, 5-FU, gemcitabine, PD-0325901, cisplatin, carboplatin, paclitaxel, bevacizumab, trastuzumab, pertuzumab, temozolomide, tamoxifen, doxorubicin, Akti-1/2, HPPD, rapamycin and lapatinib; a pharmaceutical composition of the same purpose and composition, application of the said therapeutic combination for manufacturing of medication for treatment of cancer, selected from breast cancer, cervical cancer, cancer of large intestine, endometrium, glioma, lung cancer, melanoma, ovarian cancer, cancer of pancreas and prostate, a product for treatment of a hyperproliferative disorder, including the said composition and an instruction and the product, containing the said combination for separate, simultaneous or successive application in treatment of a hyperproliferative disorder.

EFFECT: synergism of suppression of cell proliferation and regression of forms of cancer mentioned above.

45 cl, 52 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to compositions, containing an active substance. Described is a composition for the active substance delivery, which contains: a) at least, one block-copolymer, containing, at least, one poly(2-oxazoline) block A, consisting of repeating units of formula where RA stands for a hydrocarbon group, which can be optionally substituted with -OH, -SH, -COOH, -NR'2, -COOR', -CONR', -CHO, where R' stands for H or C1-3 alkyl, and RA is selected in such a way that a repeating link of formula (I) is hydrophilic; and at least one poly(2-oxazoline) block B, consisting of repeating units of formula (II), where RB stands for a hydrocarbon group, which can be optionally substituted with halogen, -OH, -SH, -COOH, -NR''2, -COOR'', -CONR'', -CHO, where R'' stands for H, alkyl or alkenyl, and RB is selected in such a way that a repeating link of formula is more hydrophobic than the repeating link of formula (I); and (b) one or more active substances. Also described is application of a copolymer for solubilisation of the active substance in water or a water solution.

EFFECT: described copolymers serve as a universal medication delivery system with high loading.

12 cl, 6 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: in formula R1 is H or (1-6C alkyl); R2 represents NRbRc, (1-4C)alkyl, (1-4C)fluoroalkyl, CF3, (1-4C)hydroxyalkyl, -(1-4Calkyl)hetAr1, -(1-4Calkyl)NH2, -(1-4C alkyl)NH(1-4Calkyl), -(1-4Calkyl)N(1-4Calkyl)2, hetAr2, hetCyc1, hetCyc2, phenyl substituted where applicable by NHSO2(1-4Calkyl) or (3-6C)cycloalkyl, substituted where applicable by (1-4C alkyl), CN, OH, OMe, NH2, NHMe, N(CH3)2, F, CF3, CO2(1-4C alkyl), CO2H; C(=O)NReRf or C(=O)ORg; Rb is H or (1-6C alkyl); Rc represents H, (1-4C)alkyl, (1-4C)hydroxyalkyl, hetAr3 or phenyl, wherein the above phenyl is substituted where applicable by one or more substitutes independently from halogen, CN, CF3 and -O(1-4C alkyl); Re represents H or (1-4C)alkyl; Rf represents H, (1-4C)alkyl or (3-6C)cycloalkyl; Rg represents H or (1-6C)alkyl; X is absent or represents -CH2-, -CH2CH2-, -CH2O- or -CH2NRd; Rd represents H or (1-4C alkyl); R3 represents H or (1-4C alkyl); and n is equal to 0-6. The radical values NRbRc, Y, hetAr1, hetAr2, hetAr3, hetCyc1, hetCyc2, NReRf, R4 are specified in the patent claim. The invention also refers to a pharmaceutical composition containing the above compounds, to a method of treating Trk kinase mediated diseases and conditions, such as pain, cancer, inflammation, neurodegenerative disease, Typanosoma cruzi infection, osteolytic disease, and to a method of preparing the above compounds.

EFFECT: invention refers to new derivatives of pyrazolo[1,5-a]pyrimidines possessing an inhibitory activity on tropomyosin-related kinases (Trk).

42 cl, 1 tbl, 105 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and concerns anthracycline conjugates with carriers, such as antibodies; methods for preparing them; a pharmaceutical composition containing them; and to using them in treating tumours in mammals.

EFFECT: group of inventions provides the high and selective effect of tumour cell destruction.

36 cl, 12 ex, 32 dwg, 7 tbl

FIELD: medicine.

SUBSTANCE: blood prostate specific antigen is measured. Radiation therapy is carried out, and Zoladex 3.6 mg is administered every 28 days before, during and after radiation. If the blood PSA is lower than 1 ng/ml three months after the beginning of the Zoladex therapy, administering the preparation is continued for the following 6 months. Radiation therapy involves a split course in the regimen of the common radiation dose fractionation to the total radiation dose 64 Gy. If the blood PSA is found to be below 1 ng/ml only six months after the beginning of the Zoladex therapy, administering the preparation is continued for the following 9 months. Radiation therapy involves the split course in the regimen of the common radiation dose fractionation to the total radiation dose 70 Gy. If the blood PSA is above 1 ng/ml six months later, Zoladex is administered in a combination with Casodex 50 mg administered daily for the following 12 months. Radiation therapy involves the split course in the regimen of the common radiation dose hypofractionation to the total radiation dose 70 Gy.

EFFECT: higher effectiveness and optimisation of treatment, substantial reduction of a number of complications on the part of a wide range of a patient's body systems, and prolonged remission.

3 ex

FIELD: medicine.

SUBSTANCE: claimed group of inventions relates to medicine, namely to oncology and radiology, and can be applied for treatment of cancer tumours. For this purpose an oil emulsion of a true solution of a radioactive salt of a short-lived isotope is introduced into a tumour in the form of separate portions by a specified programme. Also realised are the following energetic influence and control. For this purpose a coaxial sensor of temperature and/or pH are introduced into the tumour. Sensors are connected to a measuring apparatus and sources of electric impulses. Supply of electric current makes it possible to additionally realise an increase of the damaging action on irradiated cells of the cancer tumour by periodically controlled passing of series of electric impulses through the tumour until a ionisation ablation or a temperature of destruction of protein molecules and DNA of cancer cells. Also is claimed a method, which includes illumination of the tumour by an external source of directly ionising charged particles by the specified program in the form of separate portions. The coaxial sensors of temperature and/or pH, connected to the measuring apparatus and the source of electric impulses, are introduced into the cancer tumour. Supply of electric impulses in the tumour provides a local increase of the damaging action on irradiated cells of the cancer tumour until the ionising ablation or the temperature of protein molecules and DNA cancer cells destruction is provided.

EFFECT: claimed group of inventions ensures reduction of treatment terms and reduction of its trauma with more intensive destruction of cancer cells due to an additional impact of electric current with a small dose of ionising radiation.

9 cl, 2 dwg

Therapeutic device // 2522384

FIELD: medicine.

SUBSTANCE: invention relates to medical equipment. A therapeutic device contains a system of magnetic resonance tomography, adapted for obtaining a set of data of magnetic resonance tomography in a zone of visualisation, where the system of magnetic resonance tomography contains means for the magnetic field generation, a directing device, adapted for direction of a beam of charged particles into a target zone inside an object in such a way that the beam includes an angle with the magnetic field lines inside the zone of visualisation, the angle constitutes from 0 degrees to 30 degrees, where the zone of visualisation contains the target zone, means of the zone determination for determination of location of the target zone inside the subject, with application of the set of data of magnetic resonance tomography.

EFFECT: invention makes it possible to regulate a trajectory of the beam of particles without moving the object of examination.

14 cl, 4 dwg

FIELD: medicine.

SUBSTANCE: group of inventions refers to medical equipment. When implementing the method, the pathology is exposed to ionising and thermal radiation simultaneously or sequentially through an output window of a radiation source, which is placed close to or on the surface of the pathology. A radiation flux is limited to a diameter of no more than the maximum size of the pathology; a radiation energy is specified depending on the pathology thickness as shown by the relation E~Kf(d), wherein d is the pathology thickness, K is a coefficient including the radiation penetration within the human body radiation area depending on the radiation energy. The pathology is exposed to the radiation for the pre-set period of time with the source thereafter cooled down, while a cooling intensity varies depending on a temperature of the output window of the radiation source. The versions of the device design represent an enclosed probe in the form of at least two coaxial gapped thin-walled tubes having distal and proximal ends. The probe accommodates the radiation source with a cathode or an anode consisting of a base and a target, an anode cooling system and a power supply unit. The anode is placed on the distal end of the probe. According to the first version of the device, the tube gap comprises the cooling system with a heat carrier, while the cavity formed by an internal tube accommodates the cathode enclosed in an electrical insulation layer. According to the other version of the device, the tube gap accommodates the cathode in the electrical insulation layer, while the cavity formed by the internal tube comprises the cooling system.

EFFECT: group of inventions enables increasing clinical effectiveness considerably in malignant and non-malignant tumours and other diseases that are sensitive to the ionising and heat radiation by the combined and simultaneous exposure to different fluxes, as well as a power up of an X-ray source.

25 cl, 4 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to urology and oncology. A brachytherapy of prostate cancer is preceded by a transurethral prostatic resection. Tissues of an intermediate lobe of the prostate and prostatic gland are removed completely within a neck of the urinary bladder.

EFFECT: method enables reducing the volume of the prostatic gland before the impending brachytherapy, forming an optimal urethral lumen.

1 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine. Brachytherapeutic system contains: applicator for positioning radioactive granule, having multitude of hollow and extendable channels, tracking device, including sensor, containing coils or antennae, which have different orientations relative to sensor position, generator if tracking signals, made with possibility of generating signal, received by tracking device, and processor. Size and shape of tracking device make it possible for it to travel forward and backward through multitude of channels. Processor is made with possibility of obtaining measurements of position from tracking device, determination of position of multitude of channels, determination of location of multitude of channels on image, basing on said measurement of position from tracking device, and creation of plan of brachytherapy for introduction of radiation dose. Machine-readable information carrier contains code performed by computer, which realises stages of method of brachytherapeutic system application.

EFFECT: group of inventions makes it possible to reduce X-ray load and increase accuracy of brachytherapy planning.

16 cl, 6 dwg

FIELD: medicine.

SUBSTANCE: method provides conducting a radiation therapy to a total boost dose of 30-40 Gy. 60-90 Minutes before each session of the radiation therapy, 1% emoxipin is instilled 1-2 drops every 4-6 minutes for 30-40 minutes. The radiation session is immediately preceded by instillations of Coletex-gel-DNA-L hydrogel pre-dissolved in ratio 2:1 with an artificial tear preparation, 1-2 drops. Before bedtime, Coletex-gel-DNA hydrogel dissolved similarly is instilled in the same dose of 1-2 drops. After the radiation is completed, Coletex-gel-DNA hydrogel is instilled 2 times a day every 10-12 hours for 6-10 days.

EFFECT: method enables providing higher clinical effectiveness ensured by improving the protection of an anterior segment of the eyeball, reducing a degree of manifestation of radioreactions in a combination with a possibility to increase a total boost dose with no break in treatment.

4 ex

FIELD: medicine.

SUBSTANCE: there are performed beam therapy, intracavitary therapy and chemotherapy. For 5-7 days before the beginning of the radiation, Colagel-Beta with 1 β-interleukin 20 ml is introduced into a vaginal tube daily. Each session of the intracavitary therapy is preceded by introducing Colegel with 5-fluoruracil 20-25 ml into an uterine cavity and exposed for 30-40 minutes. Besides, from the beginning of the beam therapy 40-50 minutes after the radiation session, sodium alginate gel 20 ml containing methyluracil, dimethyl sulphoxide and hydrocortisone are introduced into a rectum and a bladder in a therapeutically effective amount. 5-10 procedures are performed.

EFFECT: providing faster regression of the tumour, reducing the rate and severity of radiation injuries of the rectus and bladder adjacent with the uterus with no risk of severe systemic toxic manifestations, including in senior patients with comorbid inoperable diseases and extended tumours.

3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medical equipment, namely to radiotherapeutic methods and systems. A radiotherapeutic method consists in ionising radiation pulse beam injection into an object for a pulse interval, obtaining a sampled data array of magnetic-resonant visualisation and restoring the data array with MR image formation. The sampled data array is obtained for an interval of sampled MR data longer than pulse intervals, with the sampled interval overlapping some of the pulse intervals. The data array is restored without the changed sampled MR-visualisation data obtained within the time periods of obtaining the data overlapped by the pulse intervals. The system comprises a radiotherapeutic subsystem, a MR-visualisation subsystem, a synchro unit and a restoring processor.

EFFECT: using the invention enables reducing the time of the radiotherapeutic session.

16 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine. A magazine comprises a body and a first instrument receiving the chain units and rotating in the body and having a socket or a hollow for receiving the chain units, as well as an extension spring for controlling the instrument receiving the chain units, a toothed gear fastened to the instrument receiving the chain units and rotating in the body, and an ejection unit comprising an ejection opening for ejecting radioactive emitters, and an ejection lever rotating in the body; the ejection lever is configured so that in the first position it links up with the toothed gear, and in the second position it blocks the ejection. In the above system, a further rotation of the instrument receiving the chain units after the chain unit ejection is blocked by an interaction of the chain unit following the chain unit that has been ejected, and the ejection lever.

EFFECT: patient's optimum protection against radioactive emission is provided.

15 cl, 22 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine, oncology, and can be used for treatment of extraabdominal desmoids tumours. For this purpose tumour is influenced by teletherapy in daily mode and local electromagnetic hyperthermia in two stages. Teletherapy is carried out in form of small-fraction irradiation two times per day with 4 hour interval between fractions, SFD 1.2 Gy. At the 1 stage of irradiation Summary Focal Dose constitutes 41.6 Gy and all affected muscle and tendon are included into volume of irradiation. At the II stage Summary Focal Dose constitutes 23.6-26 Gy and volume of irradiation is successively reduced to the size of detected tumour and 2-3 cm of surrounding tumour tissues. Local electromagnetic hyperthermia is performed since the second day of irradiation immediately before the second daily fraction of irradiation 2 times a week with interval 72-96 hours. Treatment is carried out at the background of daily introduction of tamoxifen in dose 20 mg two times per day.

EFFECT: method makes it possible to improve treatment results due to increase of recurrence-free period, reduction of injuring action of radiotherapy on skin and soft tissues, reduce frequency and degree of expression of early and late radiation injury of healthy organs and tissues, entering irradiation zone.

2 ex

Up!